{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-23-000014","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.744741+00:00","generated_at":"2026-06-17T16:59:51.604816+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Humacyte nears enrollment completion in two pivotal HAV trials; cash to fund ops thru 2024","bullets":["Phase 2/3 V005 trauma trial: 46 of 50 primary endpoint patients enrolled; BLA filing ~4 months after trial ends.","Phase 3 V007 AV access trial: 238 of 240 patients enrolled; topline results one year after enrollment completion.","Cash, equivalents & short-term investments: $151.9M at Dec 31, 2022, down from $225.5M; runway through end 2024.","Q4 2022 net loss $3.7M vs net income $42.6M in Q4 2021; full-year net loss $12.0M vs $26.5M in 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-23-000014","json":"https://secwatch.observer/filing/0001818382-23-000014.json","markdown":"https://secwatch.observer/filing/0001818382-23-000014.md","text":"https://secwatch.observer/filing/0001818382-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000014/0001818382-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000014/huma-20230324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T16:59:51.604816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48e70e546f14bab3546ad8aafe2e6866190ab918","claim":"Humacyte, Inc. reported financial results for fiscal fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 24, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000014/0001818382-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}